Read this issue’s cover story titled “Specialists navigate changing, challenging landscape of geographic atrophy management.” More knowledge about the diagnosis and manageme ...

Metformin use in people with diabetes was linked to a significantly lower risk of developing intermediate age-related macular degeneration.

Canaccord has a $12 price target on the stock, representing a potential upside of about 415% from the stock’s closing price ...

Geographic atrophy management could benefit greatly from the combination of novel therapies and AI-driven imaging technology.

ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the first European ...

Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal ...

Experts believe the retina may predict Alzheimer's risk because it is part of the central nervous system and connected ...

Apellis (APLS) stock gains as Roth launches its coverage with a Buy rating and a $31 target, citing its lead asset Syfovre.

Zhou lost his sight in childhood, initially thought to be caused by congenital retinal atrophy but later diagnosed as ...

Light therapy with multiple wavelengths may safely improve vision, reduce new retinal damage, and improve vision related quality of life in patients with dry age related macular degeneration.

GelMEDIX Inc., a biotechnology company developing regenerative therapies to restore vision, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients ...

FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...